Good
Mostly Aligned
Patient Risk:
Low
Summary
The response accurately reflects the label’s boxed warning concept (increased suicidal thoughts/behavior in patients age 24 and younger) and correctly states that TRINTELLIX is not established/approved for pediatric use. It is marked down for slightly imprecise phrasing about the risk attribution being described as a broad class-level effect rather than a TRINTELLIX-specific estimate, which the provided label excerpts do not quantify separately.
Category Scores
Accurate Statements
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients.
Supported by Section 5.1: pooled analyses showing increased incidence in patients age 24 and younger; also supported by Section 8.4: antidepressants such as TRINTELLIX increase the risk in pediatric patients.
TRINTELLIX is not approved for pediatric use.
Supported by Section 8.4: safety and effectiveness have not been established in pediatric patients; and Section 1 limits indication to adults.
Unsupported Statements
The risk increase is attributable to 'antidepressants' without reflecting that Section 5.1 is based on pooled analyses of multiple antidepressants (not a TRINTELLIX-specific estimate).
The claim wording is not inconsistent with the label’s general boxed-warning framing, but the provided excerpts do not quantify a TRINTELLIX-only risk estimate; the response’s phrasing is therefore only partially supported in its implied specificity.
Contradictions
Important Omissions
The response does not specify the label’s phrasing that the increased risk is for 'patients age 24 years and younger' (Section 5.1) and that risk is described in pooled analyses, not as a single drug-specific rate.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The statements concerning increased risk and lack of established pediatric safety/effectiveness are consistent with the supplied label excerpts and do not introduce incorrect or conflicting safety information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Slight imprecision: does not mirror the label’s pooled-analyses framing (Section 5.1) when stating the risk increase.
Suggested Improvement
Rephrase to align with label wording, e.g., that antidepressants (including TRINTELLIX) are associated with increased suicidal thoughts/behaviors in patients age 24 and younger, with Section 5.1 describing pooled analyses, and Section 8.4 noting pediatric safety/effectiveness have not been established.